<DOC>
	<DOCNO>NCT00775385</DOCNO>
	<brief_summary>Our hypothesis patient receive therapy base baseline tumor ERCC1 level EGFR mutation would attain good disease free survival rate patient control arm receiving noncustomized therapy . Using selective approach , patient stage II IIIA non N2 NSCLC genotypic arm low ERCC1 level receive cisplatin plus pemetrexed , high ERCC1 level receive cisplatin-based chemotherapy . If harbor EGRF mutation treat erlotinib . The study restrict non-squamous NSCLC two main reason . First , enrich EGFR mutation rate await high tumor squamous cell carcinoma . Second , permetrexed cisplatin combination promise efficacy favorable toxicity profile potential interest adjuvant set resect non-squamous NSCLC .</brief_summary>
	<brief_title>TAilored Post-Surgical Therapy Early Stage NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>NSCLC define predominantly squamous cell histology ( squamous cell and/or mixed small cell , nonsmall cell histology permit ) Surgically resect NSCLC pathological stage II stage IIIA nonN2 ( TNM classification 2008 ) Performance status ( PS ) = 0 1 18 year &lt; = age &lt; 70 year Signed inform consent Squamous cell carcinoma Previous cancer except treated 5 year consider cure , basocellular skin carcinoma , carcinoma situ uterine cervix Inadequate renal cardiac function Pregnant woman Any follow within 6 month prior study enrollment : myocardial infarction , severe/unstable angina pectoris , coronary/peripheral artery bypass graft , NYHA class III IV congestive heart failure , cerebrovascular accident transient ischemic attack , grade â‰¥ 2 peripheral neuropathy , peptic ulcer disease , erosive esophagitis gastritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Chemotherapy , Adjuvant</keyword>
</DOC>